Pan-cancer characterization of ncRNA synergistic competition uncovers potential carcinogenic biomarkers

Junpeng Zhang, Lin Liu, Xuemei Wei, Chunwen Zhao, Sijing Li, Jiuyong Li, Thuc Duy Le

TL;DR

This paper introduces SCOM, a novel computational framework to identify "synergistic competition" among non-coding RNAs (ncRNAs) across 31 cancer types. By analyzing these complex ncRNA interactions, the study uncovers potential biomarkers for cancer diagnosis, prognosis, and drug resistance, offering a new perspective on ncRNA's role in cancer.

What Problem Does This Paper Address?

Non-coding RNAs (ncRNAs) are increasingly recognized for their crucial roles in cancer development and progression. While individual ncRNAs have been studied, their collective behavior and interactions within complex regulatory networks are less understood. Specifically, the concept of competing endogenous RNAs (ceRNAs) describes how ncRNAs can "soak up" microRNAs (miRNAs), thereby influencing the expression of target messenger RNAs (mRNAs). However, this interaction is rarely a simple one-to-one relationship. This paper addresses the challenge of understanding how multiple ncRNAs might synergistically compete for the same miRNAs, impacting cancer biology. Identifying these complex interactions could reveal new insights into cancer mechanisms and lead to the discovery of novel biomarkers.

Methods

The core of this work is the SCOM (Synergistic COMpetition) framework. SCOM operates in two main steps:

  1. Predicting ncRNA-related ceRNA networks: For each of the 31 cancer types, SCOM integrates gene expression data (for miRNAs, lncRNAs, pseudogenes, and mRNAs) with existing miRNA-target interaction databases (miRTarBase, TarBase, LncBase, NPInter, ENCORI). It uses a three-criterion evaluation method (significant miRNA sharing, positive correlation, and sensitive correlation conditioning on shared miRNAs) to predict ceRNA interactions. This approach extends the SPONGE method.
  2. Inferring ncRNA synergistic competition networks: Building upon the predicted ceRNA networks, SCOM identifies synergistic competition among ncRNAs. This involves applying three criteria to pairs of ncRNAs:
  3. Significant synergistic competition with mRNAs: Assessed using a hypergeometric test.
  4. Significant positive correlation: Evaluated using Pearson correlation.
  5. Significant sensitive correlation: Assessed using partial correlation, accounting for the influence of competing mRNAs.

The framework then performs network topological analysis (degree, path length, density) and hub ncRNA identification.

Datasets

The study primarily utilizes the The Cancer Genome Atlas (TCGA) dataset, which includes:

  • Gene expression data for 17,212 ncRNAs (894 miRNAs, 4366 lncRNAs, 11,952 pseudogenes) and 19,068 mRNAs.
  • This data covers 8001 matched tumor samples across 31 tumor types.
  • Clinical information for these tumor samples.

Additionally, the study leverages data from several publicly available miRNA-target interaction databases:

  • miRTarBase v9.0
  • TarBase v8.0
  • LncBase v2.0
  • NPInter 4.0
  • ENCORI

Key Insights and Ideas

  • ncRNAs act collectively: The study moves beyond individual ncRNA function to explore how groups of ncRNAs can work together in a "synergistic competition" to regulate gene expression.
  • Hub ncRNAs are conserved: While specific ncRNA interactions are often rewired across different tumors, the hub ncRNAs (highly connected nodes in the network) show a greater degree of conservation, suggesting they might represent a common core in cancer regulation.
  • Synergistic competition links to key cancer hallmarks: The identified synergistic competition ncRNAs and hub ncRNAs are significantly enriched in pathways related to drug resistance, molecular subtyping of tumors, and immune regulation.
  • SCOMdb as a valuable resource: The development of a web-based database (SCOMdb) makes these complex ncRNA interaction networks accessible for further research.

Key Results

  • Pan-cancer landscape: SCOM successfully characterized ncRNA synergistic competition across 31 malignant tumors, revealing that these interactions are largely rewired in individual tumor microenvironments, but hub ncRNAs are more conserved.
  • Network properties: Most ncRNA synergistic competition networks exhibit scale-free and small-world network properties, indicating organized regulatory structures.
  • Biomarker potential: Conserved hub ncRNAs and synergistic competition ncRNAs demonstrated strong performance in classifying tumor types and subtypes, and distinguishing high-risk from low-risk patient groups, suggesting their utility as diagnostic and prognostic biomarkers.
  • Drug resistance association: A high percentage of synergistic competition networks (~96.77%) and hub ncRNAs (~64.52%) were significantly enriched in drug resistance terms, particularly for cisplatin, L-685458, and LBW242.
  • Molecular subtyping: Synergistic competition ncRNAs effectively assigned tumor samples into distinct molecular subtypes, with over 90% of tumors showing good subtyping performance.
  • Immune regulation: Both synergistic competition networks and hub ncRNAs were significantly involved in immune-related pathways and correlated with immune cells, highlighting their role in immune modulation within tumors.

Limitations and Future Work

  • Experimental validation: The authors acknowledge that while their findings are biologically significant, experimental validation of the predicted synergistic competition relationships is crucial.
  • Stoichiometry: The current SCOM framework does not explicitly consider the stoichiometry of miRNAs and ncRNAs, which can influence miRNA efficacy and ceRNA interactions. Future work aims to incorporate this.
  • Beyond ncRNAs: The current model focuses on ncRNA-ncRNA synergistic competition. Future extensions will investigate mRNA-mRNA and mixed ncRNA-mRNA synergistic competition.
  • Transcriptional regulation: The study primarily considers post-transcriptional regulation by miRNAs. Future research will explore the interplay between transcription factors (TFs) and miRNAs in ceRNA regulation.
  • Single-cell and spatial data: The authors suggest that with the advent of single-cell and spatial RNA sequencing, SCOM can be extended to uncover carcinogenic biomarkers at a finer resolution.
  • Data sources: While TCGA is a robust dataset, the SCOM framework can be applied to other transcriptomics data sources (e.g., CCLE, MET500) for broader applicability.

Summary updated

Abstract

Abstract Non-coding RNAs (ncRNAs) act as important modulators of gene expression and they have been confirmed to play critical roles in the physiology and development of malignant tumors. Understanding the synergism of multiple ncRNAs in competing endogenous RNA (ceRNA) regulation can provide important insights into the mechanisms of malignant tumors caused by ncRNA regulation. In this work, we present a framework, SCOM, for identifying ncRNA synergistic competition. We systematically construct the landscape of ncRNA synergistic competition across 31 malignant tumors, and reveal that malignant tumors tend to share hub ncRNAs rather than the ncRNA interactions involved in the synergistic competition. In addition, the synergistic competition ncRNAs (i.e. ncRNAs involved in the synergistic competition) are likely to be involved in drug resistance, contribute to distinguishing molecular subtypes of malignant tumors, and participate in immune regulation. Furthermore, SCOM can help to infer ncRNA synergistic competition across malignant tumors and uncover potential diagnostic and prognostic biomarkers of malignant tumors. Altogether, the SCOM framework and the resulting web-based database SCOMdb ( www.comblab.cn/SCOMdb/ ) serve as a useful resource for exploring ncRNA regulation and to accelerate the identification of carcinogenic biomarkers. Author summary Abundant evidence reveals that ncRNAs are important modulators of gene expression, and it is important for us to understand the regulation of ncRNAs in malignant tumors. In this work, we hypothesize that ncRNAs acting as ceRNAs can crosstalk with each other in the form of synergistic competition. We name the hypothesis as the ncRNA synergistic competition hypothesis . To uncover potential carcinogenic biomarkers, we present a framework, SCOM, for identifying ncRNA synergistic competition in malignant tumors. From the perspective of synergistic competition, we have shown that the synergistic competition ncRNAs are likely to involve in drug resistance, contribute to distinguishing molecular subtypes of malignant tumors, and participate in immune regulation. In addition, the synergistic competition ncRNAs are potential diagnostic and prognostic biomarkers of malignant tumors. We believe that the proposed framework SCOM and the web-based database SCOMdb can contribute to the design of reliable diagnosis and treatment biomarkers for malignant tumors.
BibTeX
@article{zhang2023pan,
  author = {Junpeng Zhang and Lin Liu and Xuemei Wei and Chunwen Zhao and Sijing Li and Jiuyong Li and Thuc Duy Le},
  title = {{Pan-cancer characterization of ncRNA synergistic competition uncovers potential carcinogenic biomarkers}},
  journal = {PLOS Computational Biology},
  year = {2023},
  doi = {10.1371/journal.pcbi.1011308},
}
Figure